The window of time is getting closer and closer, and the important strategic choice for the distribution of bio pharmaceutical enterprises

[pharmaceutical network industry trends] biomedicine is a sunrise industry, enjoying the support of many favorable policies In recent years, the growth rate of biomedicine in China is obvious Data shows that in 2018, the scale of China's pharmaceutical market has reached 1533.4 billion yuan, including 262.2 billion yuan of bio pharmaceutical market With the increasing of aging, the upgrading of consumption level and the expansion of the coverage of medical insurance, it is estimated that the market size of China's biological medicine will increase to 641.2 billion yuan by 2023 It is true that China's biopharmaceutical market is still in its infancy, but in front of a considerable market, many traditional pharmaceutical companies have begun to layout biopharmaceutics Xia Xiaoyan, partner and managing director of Boston Consulting Company, said, "now the time window is getting closer and closer, layout of biological drugs is a very important strategic choice." So, at present, which types of domestic pharmaceutical companies are laying out biological drugs? The author makes a brief inventory, which can be roughly divided into two categories 1 In recent years, a large number of traditional Chinese medicine enterprises are facing challenges due to the promotion of policies such as medical insurance fee control and proportion control With the support of biomedical industry policy, more and more traditional Chinese medicine enterprises begin to focus on the field of bio innovative medicine For example, on September 11, 2018, step pharmaceutical announced that the company will transform from a localized enterprise to a global enterprise, make full use of the advantages of the company, realize cross-border development of the pharmaceutical industry, and strive to build a biopharmaceutical industry chain and enhance the R & D strength of biopharmaceuticals In December 2018, Guizhou bailing, a domestic vaccine drug listed enterprise, cooperated with Kaine pharmaceutical on car-t cell new drugs and announced to enter the field In addition, Yunnan Baiyao, Tianshili and other large enterprises are all in the field of bio innovative medicine, and some representative enterprises of traditional Chinese medicine, such as Tianshili, have gradually entered the harvest period II The transformation of small molecule medicine enterprises from small molecule medicine to biological medicine has become the general trend of the industry Recently, LVYE pharmaceutical announced to purchase 98% of the equity of Boan biology with RMB 1.447 billion The latter is an enterprise that is committed to the development of antibody products and has been in the forefront of research and development of macromolecular drugs in China Through this transaction, LVYE pharmaceutical can not only own all products under research of Boan biology, but also include a series of assets such as antibody screening platform, intellectual property rights, antibody generation platform, etc Insiders believe that the acquisition may be a key step in the strategic transformation of LVYE pharmaceutical In terms of the research and development pipeline of biological analogues of Boan bio, the rapid progress of biological analogues is ly01008 and ly06006 (both in phase 3 clinical stage), which are expected to be listed in 2021 and 2022 respectively There are also two clinical phase 1 products, ly01011 and ly09004, which are expected to be available in 2023 In other words, from 2021, the four products are expected to bring returns to LVYE As far as I know, the annual sales volume of the original research drugs of these four products ranges from 2 billion to 7 billion, basically large varieties In addition, Boan's biological product line also includes PD-1 navurizumab, IL-17A treasurer chiyomab, GLP-1 receptor agonist trulicity and other products, with a promising market space In addition, Boan biology has more than ten candidate biological innovative products, including 4-bb antibody, PD-L1 / TGF - β bifunctional protein antibody, CGRP antibody, β - NGF antibody and other new targets In addition to LVYE pharmaceutical, Hengrui, Zhengda Tianqing and other large pharmaceutical companies have already deployed the field of biological medicine, and made relevant progress, becoming a successful case of innovation and upgrading Conclusion: in general, the prospect of biopharmaceutical market is considerable, but the industry also reminds that due to the high investment and risk of biopharmaceutical R & D, whether the enterprise can be successfully transformed, there will be great changes in the future due to policy, market competition pattern and other reasons Relatively speaking, large enterprises have greater advantages in terms of commercialization experience and human resources.